Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial

Ranjbar, Amin; Hassanzadeh, Halimeh; Jahandoust, Faezeh; Miri, Rahele; Bidkhori, Hamid Reza; Monzavi, Seyed Mostafa; Sanjar-Moussavi, Nasser; Matin, Maryam Moghaddam; Shariati-Sarabi, Zhaleh

doi:10.1016/j.retram.2021.103324

Cited by 9 publications

(14 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One patient developed transient elevated blood pressure which was successfully controlled by standard antihypertensive therapy. 14 The study by Barbado et al showed no adverse effects during MSCT infusion, immediately after infusion, or during the 9-month follow-up period. 13 The study by Deng et al showed four serious adverse effects in four patients, two in the treatment group with MSCT, and two in the control group.…”

Section: Discussionmentioning

confidence: 92%

“…From 397 studies identified at the start of the literature search, four articles are selected in this study for systematic review 12–15 . All studies are clinical trials, one of which is a randomized‐controlled trial.…”

Section: Resultsmentioning

confidence: 99%

“…16 In this systematic review, the participants mainly have refractory LN with biopsy classes III, IV-S, and IV-G based on the International Society of Nephrology and the Renal Pathology Society classification. The study by Ranjbar 2022) 14 1.8 13 The study by Deng et al included patients with classes III and IV refractory LN. 12 The study by Gu et al included patients with class III, class IV-S or IV-G, class V, class III + V, or class IV + V (within 3 months) refractory LN.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Mesenchymal stem cell transplantation as a potential therapy for refractory lupus nephritis: A systematic review

Parlindungan,

Damanik,

Araminta

et al. 2023

Rheumatology & Autoimmunity

View full text Add to dashboard Cite

BackgroundLupus nephritis (LN) results in high morbidity and mortality in patients with systemic lupus erythematosus. Refractory cases of standard immunosuppressive therapy have been recorded. Mesenchymal stem cell transplantation (MSCT) shows potential use in autoimmune diseases. We aim to review MSCT in the treatment of refractory LN.MethodsPublished articles were systematically extracted from the databases in May 2022. The quality of the studies was assessed using the Oxford Centre for Evidence‐Based Medicine critical appraisal checklist.ResultsFour studies were included. All studies recruit severe or refractory LN patients and show significant improvement in post‐MSCT 24‐h proteinuria. However, the improvement of renal function after MSCT is inconsistent between studies after a 1‐month follow‐up, with one study showing deterioration of the estimated glomerular filtration rate after 3 months and one study showing an increase in serum creatinine at 6 and 9 months. Moreover, all studies show improvement in Systemic Lupus Erythematosus Disease Activity Index scores after MSCT, while two studies show that a decrease in anti‐double‐stranded DNA (anti‐dsDNA) levels after MSCT is only evident for up to 1‐month period.ConclusionsMSCT can be effective, especially in severe or refractory LN. More randomized‐controlled trials are needed to support this evidence.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal stem cell transplantation as a potential therapy for refractory lupus nephritis: A systematic review

Parlindungan,

Damanik,

Araminta

et al. 2023

Rheumatology & Autoimmunity

View full text Add to dashboard Cite

show abstract

“…The results of treating a patient with SLE in Canada using autologous ADSCs were significant and stable 40 . A clinical trial in Iran found that ADSC transplantation is effective against LN, whereas a single dose might be insufficient to maintain remission 41 .…”

Section: Mscs In Sle Treatmentmentioning

confidence: 99%

Current Progress in Treating Systemic Lupus Erythematosus Using Exosomes/MicroRNAs

et al. 2023

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease associated with impaired organ functions that can seriously affect the daily life of patients. Recent SLE therapies frequently elicit adverse reactions and side effects in patients, and clinical heterogeneity is considerable. Mesenchymal stromal cells (MSCs) have anti-inflammatory, tissue repair, and immunomodulatory properties. Their ability to treat autoimmune diseases largely depends on secreted extracellular vesicles, especially exosomes. The effects of exosomes and microRNAs (miRNAs) on SLE have recently attracted interest. This review summarizes the applications of MSCs derived from bone marrow, adipocyte tissue, umbilical cord, synovial membrane, and gingival tissue, as well as exosomes to treating SLE and the key roles of miRNAs. The efficacy of MSCs infusion in SLE patients with impaired autologous MSCs are reviewed, and the potential of exosomes and their contents as drug delivery vectors for treating SLE and other autoimmune diseases in the future are briefly described.

show abstract

“…La nefritis lúpica es la afectación renal del lupus eritematoso, poco común y se presenta en el 2 % al 4 % de los receptores del trasplante; aunque, en ocasiones, los tratamientos convencionales como la ciclofosfa-mida y el micofenolato no son muy eficaces, el trasplante de células madre mesenquimales obtuvo un resultado positivo, en términos de disminución de la proteinuria, y mejoró significativamente la tasa de filtración glomerular; no obstante, se recomienda reposo clínico de 6 a 9 meses antes de la cirugía para no perder el injerto 41 .…”

Section: Infecciones Asociadas a Trasplanteunclassified

Pacientes con enfermedad injerto contra huésped e infecciones asociadas al rechazo de trasplante

Jaramillo¹

2023

cysa

View full text Add to dashboard Cite

Introducción: durante muchos años las células madre hematopoyéticas han sido el tratamiento para muchos trastornos hematológicos, pero su eficacia está limitada por la enfermedad injerto contra huésped (EICH); una de las principales complicaciones del trasplante alogénico se encuentra asociado con morbilidad y mortalidad, por lo tanto, la prevención es importante para el éxito del trasplante alogénico. Objetivo: realizar una revisión acerca del reconocimiento clínico de una EICH para brindar el tratamiento correcto y evitar ciertas complicaciones, como infecciones que llevan al rechazo del injerto y ponen en riesgo la calidad de vida del paciente. En la mayoría de los casos las pruebas de laboratorio como biomarcadores y biopsias, son buenos predictores para procesos biológicos o patológicos que confirmen el diagnóstico y establezcan el estadio de la enfermedad. Metodología: se realizó una revisión bibliográfica en bases de datos, tales como Pubmed y ClinicalKey, con base en los siguientes términos MeSH: cirugía, mortalidad, patología, complicaciones, virología. Conclusión: la prevención y tratamiento de esta enfermedad predispone a infecciones y diferentes complicaciones que ponen en riesgo la vida del paciente.

show abstract

Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial

Cited by 9 publications

References 54 publications

Mesenchymal stem cell transplantation as a potential therapy for refractory lupus nephritis: A systematic review

Mesenchymal stem cell transplantation as a potential therapy for refractory lupus nephritis: A systematic review

Current Progress in Treating Systemic Lupus Erythematosus Using Exosomes/MicroRNAs

Pacientes con enfermedad injerto contra huésped e infecciones asociadas al rechazo de trasplante

Contact Info

Product

Resources

About